EASL 2022

infohep news

• New and experimental treatments for hepatitis B

  Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies

  Keith Alcorn / 29 June 2022

  Bepirovirsen, an experimental drug with a novel mode of action, suppressed hepatitis B surface antigen below the limits of detection in approximately 30% of patients after 24 weeks of treatment and ...

• Hepatitis D

  Bulevirtide leads to sustained improvement for people with hepatitis D

  Liz Highleyman / 28 June 2022

  The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ...

• New and experimental treatments for hepatitis B

  Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure

  Keith Alcorn / 27 June 2022

  People with hepatitis B who received a combination of experimental drugs as well as their standard treatment for 48 weeks were significantly less likely to have high levels of hepatitis B surface ...

• Treatment for previous non-responders & relapsers

  Re-treatment of hepatitis C is highly effective after the first combination fails

  Keith Alcorn / 24 June 2022

  Two combinations proved highly effective in curing hepatitis C in people who had experienced the failure of a previous combination containing an NS5A inhibitor, studies in Europe and New Zealand show. The findings, ...

• Treatment in liver transplanted

  Short-course treatment prevents hepatitis C after organ transplant

  Keith Alcorn / 24 June 2022

  A seven-day course of direct-acting antiviral treatment started hours before an organ transplant prevented hepatitis C infection in everyone who received a transplant from a donor with hepatitis C, researchers from the Mayo ...

• Life after the cure

  People cured of hepatitis C remain at higher risk of death due to liver- and drug-related causes

  Keith Alcorn / 24 June 2022

  People who have been cured of hepatitis C remain at higher risk of dying from liver-related causes than the general population, but their risk of cardiovascular events goes down after being cured, ...